Cited by 369Liver Disease Diagnosis and TreatmentCholesterol and Lipid MetabolismCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH

Caballero, Francisco, Fernández, Anna, De Lacy, Antonio M., Fernández-Checa, Jose C., Caballería, Juan, García-Ruiz, Carmen·2009·Journal of Hepatology

DOI 10.1016/j.jhep.2008.12.016

Open this paper in CoChat — free account

Abstract

Background/aims Non-alcoholic fatty liver disease (NAFLD) pathogenesis remains unknown. Due to the emerging role of free cholesterol (FC) in NAFLD, our aim was to examine the correlation between FC accumulation in patients with NAFLD and the expression of enzymes that regulate cholesterol homeostasis. Methods Filipin staining, indicative of FC accumulation, and real-time PCR analyses were performed in 31 NAFLD patients and in seven controls. Results All NASH patients (n=14) and 4 out of 17 patients with steatosis exhibited filipin staining compared to controls (0 out of 7 subjects with normal liver histology and BMI). Sterol regulatory element-binding protein-2 (SREBP-2) mRNA levels were 7- and 3-fold higher in NASH and steatosis patients, respectively, compared to controls. Since hydroxymethylglutaryl-CoA (HMG-CoA) reductase is the key enzyme in cholesterol synthesis and transcriptionally controlled by SREBP-2 we measured its mRNA levels, being 3- to 4-fold higher in NAFLD compared to controls, without any difference between NASH and steatosis patients. Fatty acid synthase (FAS) and SREBP-1c expression were not significantly induced in NAFLD, while ATP-binding cassette sub-family G member 1 (ABCG1), a transporter involved in cholesterol egress, and acyl-CoA-cholesterol acyltransferase mRNA levels were modestly increased (1.5- to 2.5-fold, p<0.05), regardless of fibrosis. Interestingly, mRNA levels of steroidogenic acute regulatory protein (StAR), a mitochondrial-cholesterol transporting polypeptide, increased 7- and 15-fold in steatosis and NASH patients, respectively, compared to controls. Conclusions FC increases in NASH and correlates with SREBP-2 induction. Moreover, StAR overexpression in NASH suggests that mitochondrial FC may be a player in disease progression and a novel target for intervention.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2008.12.016

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Cellular cholesterol trafficking and compartmentalization
Ikonen, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2336 · Cited by 1,506

Flagged first, then by citations

Show all 39 references

1 of the 39 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 369

Critical Role of the Human ATP-Binding Cassette G1 Transporter in Cardiometabolic Diseases
Hardy, L. M., Frisdal, É., & Goff, W. L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091892 · Cited by 71
Translocator protein (18 kDa), a potential molecular imaging biomarker for non-invasively distinguishing non-alcoholic fatty liver disease
Xie, L., Yui, J., Hatori, A., Yamasaki, T., Kumata, K., Wakizaka, H., Yoshida, Y., Fujinaga, M., Kawamura, K., & Zhang, M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.002 · Cited by 68
Regulation of microRNAs and their role in liver development, regeneration and disease
Finch‐Edmondson, M., Marquardt, J. U., Yeoh, G. C., & Callus, B. A. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.04.002 · Cited by 66
Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr
Kitamori, K., Naito, H., Tamada, H., Kobayashi, M., Miyazawa, D., Yasui, Y., Sonoda, K., Tsuchikura, S., Yasui, N., Ikeda, K., et al. (2011) · Environmental Health and Preventive Medicine · doi:10.1007/s12199-011-0235-9 · Cited by 61
Targeting cholesterol at different levels in the mevalonate pathway protects fatty liver against ischemia–reperfusion injury
Llacuna, L., Fernández, A., von Montfort, C., Matías, N., Martínez-Gili, L., Caballero, F., Rimola, A., Elena, M., Morales, A., Fernández-Checa, J. C., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.031 · Cited by 62
Self-citation
3-Hydroxyanthralinic acid metabolism controls the hepatic SREBP/lipoprotein axis, inhibits inflammasome activation in macrophages, and decreases atherosclerosis in Ldlr−/− mice
Berg, M., Polyzos, K. A., Agardh, H. E., Baumgartner, R., Forteza, M. J., Kareinen, I., Gisterå, A., Böttcher, G., Hurt‐Camejo, E., Hansson, G. K., et al. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz258 · Cited by 65
Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE∗3Leiden mice
Morrison, M. C., Liang, W., Mulder, P., Verschuren, L., Pieterman, E. J., Toet, K. H., Heeringa, P., Wielinga, P. Y., Kooistra, T., & Kleemann, R. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.011 · Cited by 61
Lipid mediators of liver injury in nonalcoholic fatty liver disease
Liangpunsakul, S., & Chalasani, N. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00170.2018 · Cited by 60
Mitochondria‐Mediated Pathogenesis and Therapeutics for Non‐Alcoholic Fatty Liver Disease
Li, Z., Li, Y., Zhang, H., Guo, J., Lam, C. W. K., Wang, C., & Zhang, W. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900043 · Cited by 64
Glycine N-Methyltransferase Deficiency Affects Niemann-Pick Type C2 Protein Stability and Regulates Hepatic Cholesterol Homeostasis
Liao, Y., Chen, T.-L., Lee, T., Wang, H.-A., Wang, C.-K., Liao, L.-Y., Liu, R.-S., Huang, S.-F. K., & Chen, Y. A. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00258 · Cited by 60
A genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity
León‐Mimila, P., Vega‐Badillo, J., Gutiérrez‐Vidal, R., Villamil‐Ramírez, H., Villarreal-Molina, M. T., Larrieta‐Carrasco, E., López-Contreras, B. E., Kauffer, L. R. M., Pintado, D. G. M., Méndez‐Sánchez, N., et al. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.01.012 · Cited by 59
Resistant starch intake partly restores metabolic and inflammatory alterations in the liver of high-fat-diet-fed rats
Polakof, S., Diaz-Rubio, M. E., Dardevet, D. P., Martin, J.-F., Pujos‐Guillot, E., Scalbert, A., Sébédio, J., Mazur, A., & Comte, B. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.05.008 · Cited by 58
Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: A narrative review
Hernáez, R. (2011) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2011.08.002 · Cited by 58
Metabolomics study of the therapeutic mechanism of Schisandra Chinensis lignans in diet-induced hyperlipidemia mice
Sun, J., Liu, X., Cong, L., Li, H., Zhang, C., Chen, J., & Wang, C. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0533-3 · Cited by 57
Discovery of an insulin‐induced gene binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting sterol regulatory element‐binding protein–mediated lipogenesis
Jiang, S., Yang, X., Yang, Z., Li, J., Xu, M., Qu, Y.-X., Tang, J., Li, Y., Wang, L., Shao, Y., et al. (2022) · Hepatology · doi:10.1002/hep.32381 · Cited by 58
Glutaredoxin-1 Deficiency Causes Fatty Liver and Dyslipidemia by Inhibiting Sirtuin-1
Shao, D., Han, J., Hou, X., Fry, J., Behring, J. B., Seta, F., Long, M. T., Roy, H. K., Cohen, R. A., Matsui, R., et al. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6716 · Cited by 56
DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model
Achiwa, K., Ishigami, M., Ishizu, Y., Kuzuya, T., Honda, T., Hayashi, K., Hirooka, Y., Katano, Y., & Goto, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.12.012 · Cited by 54
Liver X receptors and liver physiology
Russo-Savage, L., & Schulman, I. G. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166121 · Cited by 55
Diabetes as a risk factor for MASH progression
Gancheva, S., Roden, M., & Castéra, L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111846 · Cited by 60
Metabolic and immune impairments induced by the endocrine disruptors benzo[ a ]pyrene and triclosan in Xenopus tropicalis
Regnault, C., Willison, J. C., Veyrenc, S., Airieau, A., Méresse, P., Fortier, M., Fournier, M., Brousseau, P., Raveton, M., & Reynaud, S. (2016) · Chemosphere · doi:10.1016/j.chemosphere.2016.04.047 · Cited by 54
Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high‐fat diet
Miura, K., Ohnishi, H., Morimoto, N., Minami, S., Ishioka, M., Watanabe, S., Tsukui, M., Takaoka, Y., Nomoto, H., Isoda, N., et al. (2018) · Cancer Science · doi:10.1111/cas.13902 · Cited by 54
Human-based systems: Mechanistic NASH modelling just around the corner?
Boeckmans, J., Natale, A., Buyl, K., Rogiers, V., Kock, J. D., Vanhaecke, T., & Rodrigues, R. M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.029 · Cited by 55
SREBP‐2: A link between insulin resistance, hepatic cholesterol, and inflammation in NASH
Rooyen, D. M. V., & Farrell, G. C. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06704.x · Cited by 53
Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression
Azzu, V., Vacca, M., Kamzolas, I., Hall, Z., Leslie, J., Carobbio, S., Virtue, S., Davies, S. E., Lukasik, A., Dale, M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101210 · Cited by 52
Lysosomal cholesterol overload in macrophages promotes liver fibrosis in a mouse model of NASH
Itoh, M., Tamura, A., KANAI, S., Tanaka, M., Kanamori, Y., Shirakawa, I., Ito, A., Oka, Y., Hidaka, I., Takami, T., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20220681 · Cited by 52
Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review
Li, X., Sui, J.-Q., Lu, L., Zhang, N., Xu, X. Y., Dong, Q., Xin, Y., & Xuan, S. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0221-8 · Cited by 53
Cholesterol overload in the liver aggravates oxidative stress-mediated DNA damage and accelerates hepatocarcinogenesis
Enríquez‐Cortina, C., Bello‐Monroy, O., Rosales-Cruz, P., Souza, V., Miranda, R. U., Toledo-Pérez, R., Luna‐López, A., Nieves, A. S., Hernández‐Pando, R., Gutiérrez‐Ruíz, M. C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22024 · Cited by 54
Improving dietary patterns in patients with nonalcoholic fatty liver disease
Carvalhana, S. C., Machado, M. V., & Cortez‐Pinto, H. (2012) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e3283566614 · Cited by 52
Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease
Steensels, S., Qiao, J., & Ersoy, B. A. (2020) · Metabolites · doi:10.3390/metabo10070283 · Cited by 53
MITOCHONDRIAL CHOLESTEROL AND CANCER
García‐Ruiz, C., de la Rosa, L. C., Ribas, V., & Fernández-Checa, J. C. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.014 · Cited by 55
Self-citation
Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease
Musso, G., Cassader, M., & Gambino, R. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834c37ee · Cited by 50
Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis
Torres, S., Segalés, P., García‐Ruiz, C., & Fernández-Checa, J. C. (2022) · Cells · doi:10.3390/cells11091475 · Cited by 51
Self-citation
The molecular pathogenic role of inflammatory stress in dysregulation of lipid homeostasis and hepatic steatosis
Chen, Y., Varghese, Z., & Ruan, X. Z. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.07.007 · Cited by 54
Normal weight dyslipidemia: Is it all about the liver?
Ipsen, D. H., Tveden‐Nyborg, P., & Lykkesfeldt, J. (2016) · Obesity · doi:10.1002/oby.21443 · Cited by 51
Inflammatory stress exacerbates hepatic cholesterol accumulation via disrupting cellular cholesterol export
Chen, Y., Chen, Y., Zhao, L., Chen, Y., Mei, M., Li, Q., Ailong, H., Varghese, Z., Moorhead, J. F., & Ruan, X. Z. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06986.x · Cited by 50
Sortilin 1 Modulates Hepatic Cholesterol Lipotoxicity in Mice via Functional Interaction with Liver Carboxylesterase 1
Li, J., Wang, Y., Matye, D. J., Chavan, H. D., Krishnamurthy, P. C., Li, F., & Li, T. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.762005 · Cited by 52
Desmosterol in Human Nonalcoholic Steatohepatitis
Simonen, M., Männistö, V., Leppänen, J., Kamińska, D., Kärjä, V. J., Venesmaa, S., Käkelä, P., Kuusisto, J., Gylling, H., Laakso, M., et al. (2013) · Hepatology · doi:10.1002/hep.26342 · Cited by 49
Eicosapentaenoic acid-enriched phospholipids improve atherosclerosis by mediating cholesterol metabolism
Ding, L., Zhang, L., Wen, M., Che, H., Du, L., Wang, J., Xue, C., Xu, J., & Wang, Y. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.02.020 · Cited by 48
Apigenin reduces the excessive accumulation of lipids induced by palmitic acid via the AMPK signaling pathway in HepG2 cells
Lu, J., Meng, Z., Cheng, B., Liu, M., Tao, S., & Guan, S. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7905 · Cited by 48
Interaction effect between NAFLD severity and high carbohydrate diet on gut microbiome alteration and hepatic de novo lipogenesis
Kang, H., You, H. J., Lee, G., Lee, S. H., Yoo, T., Choi, M., Joo, S. K., Park, J. H., Chang, M. S., Lee, D. H., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2078612 · Cited by 47
Pyroptosis in Steatohepatitis and Liver Diseases
Knorr, J., Wree, A., & Feldstein, A. E. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167271 · Cited by 48
Rapid Development of Non-Alcoholic Steatohepatitis in Psammomys obesus (Israeli Sand Rat)
Spolding, B., Connor, T., Wittmer, C., de Abreu, L. L. F., Kaspi, A., Ziemann, M., Kaur, G., Cooper, A., Morrison, S., Lee, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092656 · Cited by 46
Transient Hepatic Overexpression of Insulin-Like Growth Factor 2 Induces Free Cholesterol and Lipid Droplet Formation
Kessler, S. M., Laggai, S., Wonterghem, E. V., Gemperlein, K., Müller, R., Haybaeck, J., Vandenbroucke, R. E., Ogris, M., Libert, C., & Kiemer, A. K. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00147 · Cited by 44
Ces3/TGH Deficiency Attenuates Steatohepatitis
Lian, J., Wei, E., Groenendyk, J., Das, S. K., Hermansson, M., Li, L., Watts, R., Thiesen, A., Oudit, G. Y., Michalak, M., et al. (2016) · Scientific Reports · doi:10.1038/srep25747 · Cited by 44
Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease
Kotlyarov, S. N., & Bulgakov, A. (2021) · Cells · doi:10.3390/cells10112978 · Cited by 45
The IGF2 mRNA binding protein p62/IGF2BP2-2 induces fatty acid elongation as a critical feature of steatosis
Laggai, S., Kessler, S. M., Boettcher, S., Lebrun, V., Gemperlein, K., Lederer, E., Leclercq, I. A., Mueller, R., Hartmann, R. W., Haybaeck, J., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m045500 · Cited by 45
Bavachinin inhibits cholesterol synthesis enzyme FDFT1 expression via AKT/mTOR/SREBP-2 pathway
Dong, X., Zhu, Y., Wang, S., Luo, Y., Lu, S., Nan, F., Sun, G., & Sun, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106865 · Cited by 43
Hepatocyte Growth Factor Reduces Free Cholesterol‐Mediated Lipotoxicity in Primary Hepatocytes by Countering Oxidative Stress
Domínguez‐Pérez, M., Nuño‐Lámbarri, N., Clavijo‐Cornejo, D., Luna‐López, A., Souza, V., Bucio, L., Miranda, R. U., Muñoz-Espinosa, L. E., Gómez-Quiroz, L. E., Uribe‐Carvajal, S., et al. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7960386 · Cited by 42
Liver Cholesterol Overload Aggravates Obstructive Cholestasis by Inducing Oxidative Stress and Premature Death in Mice
Nuño‐Lámbarri, N., Domínguez‐Pérez, M., Anna, B., Monte, M. J., Marı́n, J. J. G., Rosales-Cruz, P., Souza, V., Miranda, R. U., Bucio, L., Montalvo-Jave, E. E., et al. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9895176 · Cited by 42
Self-citation
G protein-coupled receptor 35 attenuates nonalcoholic steatohepatitis by reprogramming cholesterol homeostasis in hepatocytes
Wei, X., Yin, F., Wu, M., Xie, Q., Zhao, X., Zhu, C., Xie, R.-Q., Chen, C., Liu, M., Wang, Y., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.011 · Cited by 41
Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis
Simon, Y., Kessler, S. M., Gemperlein, K., Bohle, R. M., Müller, R., Haybaeck, J., & Kiemer, A. K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i47.17839 · Cited by 41
Liver cholesterol: is it playing possum in NASH?
Farrell, G. C., & Rooyen, D. M. V. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00008.2012 · Cited by 41
Cholesterol is a significant risk factor for non-alcoholic steatohepatitis
Walenbergh, S. M. A., & Shiri‐Sverdlov, R. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1092382 · Cited by 41
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Patterns of cholesterol metabolism: Pathophysiological and therapeutic implications for dyslipidemias and the metabolic syndrome
Lupattelli, G., VUONO, S. D., & Mannarino, E. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2011.04.010 · Cited by 40
Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
Scarpellini, E., Scarcella, M., Tack, J. F., Scarlata, G. G. M., Zanetti, M., & Abenavoli, L. (2024) · Antioxidants · doi:10.3390/antiox13111386 · Cited by 48
Dysregulated Bile Acid Synthesis, Metabolism and Excretion in a High Fat-Cholesterol Diet-Induced Fibrotic Steatohepatitis in Rats
Jia, X., Naito, H., Yetti, H., Tamada, H., Kitamori, K., Hayashi, Y., Wang, D., Yanagiba, Y., Wang, J., Ikeda, K., et al. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2747-1 · Cited by 39
Steatosis and Steatohepatitis: Complex Disorders
Bettermann, K., Hohensee, T., & Haybaeck, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15069924 · Cited by 41
Cholesterol Induces Nrf-2- and HIF-1 α-Dependent Hepatocyte Proliferation and Liver Regeneration to Ameliorate Bile Acid Toxicity in Mouse Models of NASH and Fibrosis
Kaminsky-Kolesnikov, Y., Rauchbach, E., Abu-Halaka, D., Hahn, M., García-Ruiz, C., Fernandez-Checa, J. C., Madar, Z., & Tirosh, O. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5393761 · Cited by 39
Self-citation
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
Lee, H. Y., Jun, D. W., Kim, H. J., Oh, H., Saeed, W. K., Ahn, H. S., Cheung, R. C., & Nguyen, M. H. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.194 · Cited by 39
Caffeine programs hepatic SIRT1-related cholesterol synthesis and hypercholesterolemia via A2AR/cAMP/PKA pathway in adult male offspring rats
Hu, S., Liu, K., Luo, H., Xu, D., Chen, L., Zhang, L., & Wang, H. (2019) · Toxicology · doi:10.1016/j.tox.2019.02.015 · Cited by 38
Hepatocyte sortilin 1 knockout and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in Western diet-fed mice
Chen, C., Li, J., Matye, D. J., Wang, Y., & Li, T. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m089789 · Cited by 37
Enhanced Gastrointestinal Expression of Cytosolic Malic Enzyme (ME1) Induces Intestinal and Liver Lipogenic Gene Expression and Intestinal Cell Proliferation in Mice
Al‐Dwairi, A., Brown, A. R., Pabona, J. M. P., Van, T. H., Hamdan, H., Mercado, C. P., Quick, C. M., Wight, P. A., Simmen, R. C. M., & Simmen, F. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113058 · Cited by 38
Hepatocarcinogenesis and Ceramide/Cholesterol Metabolism
Morales, A., Marı́, M., García‐Ruiz, C., Colell, A., & Fernández-Checa, J. C. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012800228689 · Cited by 35
Self-citation
Pro‐inflammatory signalling and gut‐liver axis in non‐alcoholic and alcoholic steatohepatitis: Differences and similarities along the path
Glaser, T., Baiocchi, L., Zhou, T., Francis, H., Lenci, I., Grassi, G. B., Kennedy, L. L., Liangpunsakul, S., Glaser, S. S., Alpini, G. D., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15182 · Cited by 35
Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD)
Vos, D. Y., & van de Sluis, B. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101146 · Cited by 35
HCV Infection and Metabolic Syndrome: Which Is the Chicken and Which Is the Egg?
Negro, F. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.063 · Cited by 34
Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver
Núñez-García, M., Gómez‐Santos, B., Buqué, X., García‐Rodríguez, J. L., Romero, M. R., Marı́n, J. J. G., Arteta, B., García‐Monzón, C., Castaño, L. A., Syn, W., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m078980 · Cited by 34
Lipid and Lipoprotein Metabolism in Liver Disease
Arvind, A., Osganian, S. A., Cohen, D. E., & Corey, K. E. (2015) · MDText.com, Inc. eBooks · Cited by 35
Immunoregulation by lipids during the development of non-alcoholic steatohepatitis.
Ramadori, P., Kroy, D. C., & Streetz, K. L. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2015.01.02 · Cited by 31
Arid1a Loss Drives Nonalcoholic Steatohepatitis in Mice Through Epigenetic Dysregulation of Hepatic Lipogenesis and Fatty Acid Oxidation
Moore, A., Wu, L., Chuang, J.-C., Sun, X., Luo, X., Gopal, P., Li, L., Celen, C., Zimmer, M., & Zhu, H. (2018) · Hepatology · doi:10.1002/hep.30487 · Cited by 32
From Liver Fat to Cancer: Perils of the Western Diet
Kim, J. Y., He, F., & Karin, M. (2021) · Cancers · doi:10.3390/cancers13051095 · Cited by 32
Ces3/TGH Deficiency Improves Dyslipidemia and Reduces Atherosclerosis in Ldlr −/− Mice
Lian, J., Quiroga, A. D., Li, L., & Lehner, R. S. (2012) · Circulation Research · doi:10.1161/circresaha.112.267468 · Cited by 32
Hepatic metabolomics and transcriptomics to study susceptibility to ketosis in response to prepartal nutritional management
Shahzad, K., Lopreiato, V., Liang, Y., Trevisi, E., Osorio, J. S., Xu, C., & Loor, J. J. (2019) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-019-0404-z · Cited by 33
Management of fatty liver disease with the metabolic syndrome
Machado, M. V., & Cortez‐Pinto, H. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.903798 · Cited by 31
NPY stimulates cholesterol synthesis acutely by activating the SREBP2-HMGCR pathway through the Y1 and Y5 receptors in murine hepatocytes
Chen, F., Zhou, Y., Yang, K., Shen, M., & Wang, Y. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118478 · Cited by 30
Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine
Mueller, A. M., Kleemann, R., Gart, E., van Duyvenvoorde, W., Verschuren, L., Caspers, M., Menke, A., Krömmelbein, N., Salic, K., Burmeister, Y., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.601160 · Cited by 29
Acupuncture on ST36, CV4 and KI1 Suppresses the Progression of Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease in Mice
Meng, X., Guo, X., Zhang, J., Moriya, J., Kobayashi, J., Yamaguchi, R., & Yamada, S. (2019) · Metabolites · doi:10.3390/metabo9120299 · Cited by 30
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Vitulo, M., Gnodi, E., Rosini, G., Meneveri, R., Giovannoni, R., & Barisani, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612748 · Cited by 36
Oxysterols and redox signaling in the pathogenesis of non-alcoholic fatty liver disease
Serviddio, G., Blonda, M., Bellanti, F., Villani, R., Iuliano, L., & Vendemiale, G. (2013) · Free Radical Research · doi:10.3109/10715762.2013.835048 · Cited by 29
The allegheny general modification of the Harvard Breast Cosmesis Scale for the retreated breast.
Trombetta, M. G., Julian, T. B., Kim, Y., Werts, E. D., & Parda, D. S. (2009) · PubMed · Cited by 29
EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis
Ma, F., Longo, M., Meroni, M., Bhattacharya, D., Paolini, E., Mughal, S., Hussain, S., Anand, S. K., Gupta, N., Zhu, Y., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.020 · Cited by 29
Ileal microbial microbiome and its secondary bile acids modulate susceptibility to nonalcoholic steatohepatitis in dairy goats
Wang, Y., Chen, X., Huws, S., Xu, G., Li, J., Ren, J., Xu, J., Guan, L. L., Yao, J., & Wu, S. (2024) · Microbiome · doi:10.1186/s40168-024-01964-0 · Cited by 31
l -Methionine supplementation attenuates high-fat fructose diet-induced non-alcoholic steatohepatitis by modulating lipid metabolism, fibrosis, and inflammation in rats
Navik, U., Sheth, V. G., Sharma, N., & Tikoo, K. (2022) · Food & Function · doi:10.1039/d1fo03403k · Cited by 28
Mitochondrial Cholesterol Metabolites in a Bile Acid Synthetic Pathway Drive Nonalcoholic Fatty Liver Disease: A Revised “Two-Hit” Hypothesis
Kakiyama, G., Rodríguez‐Agudo, D., & Pandak, W. M. (2023) · Cells · doi:10.3390/cells12101434 · Cited by 30
Cholesterol Synthesis Is Associated with Hepatic Lipid Content and Dependent on Fructose/Glucose Intake in Healthy Humans
Silbernagel, G., Lütjohann, D., Machann, J., Meichsner, S., Kantartzis, K., Schick, F., Häring, H., Stefan, N., & Fritsche, A. (2011) · Experimental Diabetes Research · doi:10.1155/2012/361863 · Cited by 30
P2X7 Receptor as a Key Player in Oxidative Stress-Driven Cell Fate in Nonalcoholic Steatohepatitis
Chatterjee, S., & Das, S. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/172493 · Cited by 29
Rapid diagnostics of liver steatosis by Raman spectroscopy via fiber optic probe: a pilot study
Pacia, M. Z., Czamara, K., Zebala, M., Kuś, E., Chłopicki, S., & Kaczor, A. (2018) · The Analyst · doi:10.1039/c8an00289d · Cited by 28
Fatty liver without a large “belly”: Magnified review of non-alcoholic fatty liver disease in non-obese patients
Yousef, M., Juboori, A. A., Albarrak, A. A., Ibdah, J. A., & Tahan, V. (2017) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v8.i3.100 · Cited by 27
Inhibition of TREM‐1 attenuates inflammation and lipid accumulation in diet‐induced nonalcoholic fatty liver disease
Rao, S., Huang, J., Shen, Z., Xiang, C., Zhang, M., & Lu, X. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28468 · Cited by 27
Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
Dongiovanni, P., Meroni, M., Longo, M., Fargion, S. R., & Fracanzani, A. L. (2021) · Biomedicines · doi:10.3390/biomedicines9111524 · Cited by 27
Cholesterol accumulation in hepatocytes mediates IRE1/p38 branch of endoplasmic reticulum stress to promote nonalcoholic steatohepatitis
Sözen, E., Demirel-Yalçıner, T., Sari, D., & Özer, N. K. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.08.024 · Cited by 27
Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease
Gillard, J., & Leclercq, I. A. (2023) · Clinical Science · doi:10.1042/cs20220697 · Cited by 29
Steatohepatitis in laboratory opossums exhibiting a high lipemic response to dietary cholesterol and fat
Chan, J., Sharkey, F. E., Kushwaha, R. S., VandeBerg, J. F., & VandeBerg, J. L. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00415.2011 · Cited by 27
Visceral fat positively correlates with cholesterol synthesis in dyslipidaemic patients
Lupattelli, G., Pirro, M., Mannarino, M. R., Siepi, D., Roscini, A. R., Schillaci, G., & Mannarino, E. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02572.x · Cited by 28
New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance
Karin, M. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby005 · Cited by 27
Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease
Okamoto, K., Koda, M., Okamoto, T., Onoyama, T., Miyoshi, K., Kishina, M., Matono, T., Kato, J., Tokunaga, S., Sugihara, T., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0219412 · Cited by 27
Mitochondrial ROS, a trigger for mitochondrial dysfunction and inflammasome activation and a therapeutic target in liver diseases
Jaara, H. S., & Torres, S. (2024) · Exploration of Digestive Diseases · doi:10.37349/edd.2024.00062 · Cited by 30
From Non-Alcoholic Fatty Liver to Hepatocellular Carcinoma: A Story of (Mal)Adapted Mitochondria
Amorim, R., Magalhães, C. C., Borges, F., Oliveira, P. J., & Teixeira, J. (2023) · Biology · doi:10.3390/biology12040595 · Cited by 28
Pathophysiological mechanisms and therapeutic potentials of macrophages in non-alcoholic steatohepatitis
Wu, R., Nakatsu, G., Zhang, X., & Yu, J. Q. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1125883 · Cited by 26

Authors: Caballero, F., Fernández, A., De Lacy, A. M., Fernández-Checa, J. C., Caballería, J., & García-Ruiz, C.
Affiliations: Consejo Superior de Investigaciones Científicas (ES)
ORCID: Caballería, Juan
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2009-04
Volume: 50
Issue: 4
Pages: 789-796
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2008.12.016
OpenAlex: W2010101404
Cited by: 368
References: 39
Citations by year: 2026: 9 · 2025: 21 · 2024: 25 · 2023: 26 · 2022: 18 · 2021: 24 · 2020: 28 · 2019: 18 · 2018: 27 · 2017: 24 · 2016: 30 · 2015: 20 · 2014: 21 · 2013: 22 · 2012: 15
FWCI: 12.37
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (P50-AA11999, P50AA011999)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, free cholesterol, SREBP2, steroidogenic acute regulatory protein, cholesterol homeostasis, HMG-CoA reductase, ABCG1, acyl-CoA:cholesterol acyltransferase, fatty acid synthase, SREBP-1c, mitochondrial cholesterol transport, steatosis, fibrosis
MeSH terms: ATP Binding Cassette Transporter, Subfamily G, Member 1, Steroidogenic Acute Regulatory Protein, Adult, Animals, Cholesterol, Fatty Liver, Female, Filipin, Humans, Hydroxymethylglutaryl CoA Reductases, Male, Middle Aged, Obesity, Morbid, Phosphoproteins, RNA, Messenger, DNA Primers, Mice, Knockout, ATP-Binding Cassette Transporters, Reverse Transcriptase Polymerase Chain Reaction, Diabetes Complications, Mice, Sterol Regulatory Element Binding Protein 1, Sterol Regulatory Element Binding Protein 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks